Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Is treatment working?

Chapter 09 · Patients & families

Is treatment working?

Inflammation, accumulated damage and the impact of symptoms should be followed separately. One number cannot capture every part of SpA.

Olga Goodman, MD · Evidence checked: 25 September 2026

Look for meaningful change

Less swelling, easier movement, better sleep and restored activities can be important outcomes. Blood tests and examinations add information. Normal CRP does not prove that every domain is controlled, and a raised result may have another cause such as infection.

Different measures for different patterns

For axial disease, clinicians may use ASDAS and patient-reported measures such as BASDAI, alongside function and mobility. In PsA, joint counts, skin, entheses, digits, function and the person’s experience need attention. A measure focused on joints may miss troublesome psoriasis or axial symptoms.

Remission is not a promise of no symptoms

Low inflammatory activity can coexist with structural limitation, tendon pain, poor sleep or amplified pain processing. The aim is to recognise and address those problems. At the same time, persistent pain should not be dismissed without checking for ongoing or newly active inflammation.

When a medicine seems to have failed

Review whether the target was appropriate, the treatment was taken as intended, enough time has passed, and a relevant dose or schedule was used. Consider adverse effects and additional conditions. A change in strategy should follow an explanation of the remaining problem, rather than a pain score alone.

Sources & further reading
  1. ASAS–EULAR axSpA management recommendations: 2022 update
  2. EULAR PsA pharmacological recommendations: 2023 update, published 2024
  3. EULAR recommendations for fatigue in inflammatory rheumatic diseases (2023)

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Spondyloarthritis